Causes Of Thrombophlebitis: Risk Factors And Underlying Conditions
Published on: September 17, 2025
Causes Of Thrombophlebitis: Risk Factors And Underlying Conditions.
Article author photo

Dr. Neha Mistry

Bachelor of Dental Surgery- B.D.S., Mumbai, India

Thrombophlebitis

Thrombophlebitis is the inflammation of a vein due to the presence of a thrombus (blood clot), obstructing the lumen of the vein.

It obstructs the flow of blood, which can present itself clinically as pain, swelling, redness and local or systemic increase in body temperature. 

It can affect the veins that are towards the surface of the skin or the deeper veins. It is called superficial vein thrombosis or deep vein thrombosis, respectively. Deep vein thrombosis can lead to pulmonary embolism, which can pose a significant risk. This makes it imperative to understand the risk factors and underlying conditions that cause thrombophlebitis.

The process of blood clot formation

It starts with an injury to the blood vessel lining. The damaged lining releases tissue factor. In the presence of calcium ions, thromboplastin converts prothrombin to thrombin. Thrombin converts fibrinogen to fibrin. The fibrin aggregates to form a net which houses red blood cells, platelets, and collagen fibres to form a clot. This is a protective mechanism of the body to prevent blood loss whenever there is trauma. But when this process starts within the blood vessels, obstructing the blood flow, it becomes a health hazard.

Risk factors for thrombophlebitis

Patient factors

  • Age : 
    • Superficial venous thrombosis usually affects women who are older than 60 years of age and whose body mass index is greater than 251
  • Obesity: 
    • Obesity is a chronic inflammatory condition wherein the adipocytes secrete larger amounts of inflammatory cytokines, and the impaired fibrinolytic activity predisposes a patient to intravascular thrombus formation. This leads to migration of macrophages to the adipose tissue. This tissue is found more in the visceral areas than the superficial areas of the body. Tumour necrosis factors, interleukin 6, are in turn increased and contribute to maintaining the chronic inflammatory state of the body
  • Chronic Inflammation
    • Chronic inflammation causes dysfunction of the inherent anticoagulant pathways of the body, like the tissue factor pathway inhibitor, protein C, etc and increases the possibility of thrombus formation
  • Varicose veins
    • Studies show that varicose veins and increased height are contributing factors for deep vein thrombosis21
  • Previous Deep Vein Thrombosis
    • Patients with previous thromboembolic episodes are more prone to have a repeat occurrence
  • Oral contraceptives
    • The use of oestrogen and progesterone creates hypercoagulation states in the body by promoting transcription of genes for multiple coagulation factors.23 In addition to this, non-aspirin NSAIDs also cause deep vein thrombosis, and the patients who are prescribed these medications should be informed of the side effects of the same.
  • Pregnancy /Puerperium
    • Pregnancy is associated with increased coagulability of blood and lessened destruction of fibrin. While this ensures that there is limited blood loss during the delivery, it also carries a greater risk of deep vein thrombosis, which can be potentially life-threatening. Altered platelet function during pregnancy and triggered response to inflammatory mediators like ADP leads to increased platelet aggregation at the injury site. There is venous stasis due to dilation of the veins in response to oestrogen and progesterone. The rate of blood flow is reduced, and the uterus compresses the iliac veins. This completes Virchow's triad. Pertinent measures need to be taken at this time to reduce deep vein thrombosis
  • Dehydration
    • Dehydration does not cause thromboembolism and thrombophlebitis by itself, but in compromised patients, it does increase the risk of superficial or deep vein thrombosis.27,28
  • Immobility 
    • Patients who are confined to their beds for prolonged periods, especially after a stroke, heart failure, respiratory failure etc are at an increased risk of deep vein thrombosis.28

Surgical risk factors

The incidence of deep vein thrombosis in patients who have had surgery done recently depends upon the age, the type of surgery done, obesity, underlying risk factors like coagulation defects or comorbidities like myocardial infarction or stroke.

Patients who undergo surgery on the lower extremities, like knee arthroplasty or hip fracture surgery, are at increased risk for deep vein thrombosis.

Underlying medical conditions contributing to thrombophlebitis

  • Myocardial infarction or heart failure:
    • Myocardial infarction occurs when one of the coronary arteries is occluded by a thrombus, leading to impaired cardiac muscle function. Atherosclerosis of the arteries is the underlying risk factor wherein the atherosclerotic plaque in the walls of the affected artery, inflammation and unstable nature of the plaque can lead to dislodging of the plaque and formation of the thrombus, which will move further down to occlude an artery
    • The mortality rate is 5% -10% in patients with myocardial infarction. The only alternative to restore the cardiac muscle is to revascularise it as soon as possible. It cannot be revived otherwise
  • Inflammatory bowel disease
    • It includes Crohn's disease, ulcerative colitis, etc
    • Virchow's triad is present during inflammatory bowel disease, too. The coagulation irregularities seen in Inflammatory Bowel Disease are:
      • Elevated levels of coagulation factors- V, VIII, Von Willebrand and fibrinogen
      • Products of fibrin and thrombin production
      • Increased markers of vascular endothelial activation
      • Dysfunction and deficiencies of natural anticoagulants
      • Defects in fibrinolytic pathways
      • Elevated levels of platelets
      • Decreased levels of anti-inflammatory bacteria like Faecalibacterium prausnitzii. An altered microbiome in the intestine leads to improper digestion of food, which further increases the inflammation35
  • Malignancy:
    • Thrombosis during chemotherapy and due to malignancy is due to mucin-producing carcinomas. These mucins are secreted in the blood after defective glycosylation. The liver gets rid of almost all these mucins, but some are resistant. These act on the L-selection adhesion molecules on leukocytes and P-selectin adhesion molecules on platelets and endothelial cells, producing microthrombi. Cancer cells secrete abnormally high tissue factor( which is highly procoagulant) and also induce monocytes and macrophages to release tissue factor. The Tissue Factor converts factor VII to VIIa. Cysteine proteinase (also a form of cancer procoagulant) induces the conversion of factor X to Xa. This leads to coagulation
  • Nephrotic syndrome
    • Nephrotic syndrome is defined by the presence of nephrotic proteinuria, peripheral edema, hypoalbuminemia, hyperlipidemia and venous thrombo-embolic complications.37 There is damage to the glomerular membrane, which increases its permeability to proteins like antithrombin III, plasminogen, protein C, and protein S, which increases coagulability. Also, the loss of albumin makes the liver secrete more fibrinogen, which increases the possibility of thrombus formation
  • Pneumonia
    • Pneumonia is caused by mycoplasma pneumoniae. It causes thrombosis after about 3 days to 3 weeks of infection. The mechanism of action also seems to be hypercoagulability and vascular injury. M. pneumoniae harbors itself in the atherosclerotic plaques and travels with the dismembered clot from the blood vessel wall. Patients with familial thrombophilia are more at risk of developing a thrombus due to increased homocysteine level and decreased folic acid levels. The infection also increases the factors of the intrinsic pathway, increases cold agglutinins and increases levels of protein C and protein S.
  • Other hematologic disorders
    • Deficiencies of the following factors can cause thrombosis:
      • Antithrombin deficiency
      • Protein C and S deficiency
      • Factor V Leiden
      • Prothrombin G20210A
      • Antiphospholipid antibody syndrome

Conclusion

Thrombophlebitis is a condition occurring due to multiple risk factors, which may or may not be modified. The lifestyle choices, medications and preventive measures can help in controlling the disease a bit. Healthcare personnel should keep a constant lookout for these symptoms so that a major medical emergency can be averted.

References

  1. Davidson, Leybourne S., et al., editors. Davidson’s Principles and Practice of Medicine. 20. Edition, Elsevier Churchill Livingstone, 2006.
  2. Cansin, Fevzi, et al. “Relapsing Superficial Thrombophlebitis Attacks Following Inactive COVID-19 Vaccination (Sinovac/CoronaVac) in aPreviously Inactive Patient with Behçet Disease.” Turkiye Klinikleri Journal of Case Reports, vol. 31, no. 2, 2023, pp. 86–88. DOI.org (Crossref), https://doi.org/10.5336/caserep.2023-95262.
  3. Bauersachs, Rupert, et al. ‘Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT)’. European Journal of Vascular and Endovascular Surgery, vol. 62, no. 2, Aug. 2021, pp. 241–49. DOI.org (Crossref), https://doi.org/10.1016/j.ejvs.2021.04.015.
  4. Cansin, Fevzi, et al. ‘Relapsing Superficial Thrombophlebitis Attacks Following Inactive COVID-19 Vaccination (Sinovac/CoronaVac) in aPreviously Inactive Patient with Behçet Disease’. Turkiye Klinikleri Journal of Case Reports, vol. 31, no. 2, 2023, pp. 86–88. DOI.org (Crossref), https://doi.org/10.5336/caserep.2023-95262.
  5. Carrier M, Blais N, Crowther M, Kavan P, Le Gal G, Moodley O, Shivakumar S, Suryanarayan D, Tagalakis V, Wu C, Lee AY. Treatment algorithm in cancer-associated thrombosis: updated Canadian expert consensus. Current Oncology. 2021 Dec 18;28(6):5434-51.
  6. Jud, Philipp, and Jürgen Prattes. ‘Bilateral Necrotizing Polymicrobial Thrombophlebitis’. Balkan Medical Journal, vol. 39, no. 4, July 2022, pp. 297–98. DOI.org (Crossref), https://doi.org/10.4274/balkanmedj.galenos.2022.2022-3-60.
  7. Jinna S, Khoury J. Migratory Thrombophlebitis. [Updated 2022 Sep 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-
  8. Litzendorf, Maria, and Maria Litzendorf. ‘Superficial Venous Thrombosis: Disease Progression and Evolving Treatment Approaches’. Vascular Health and Risk Management, Aug. 2011, p. 569. DOI.org (Crossref), https://doi.org/10.2147/VHRM.S15562.
  9. Almeida, Marcelo José De, et al. ‘Diretrizes de Conceito, Diagnóstico e Tratamento Da Trombose Venosa Superficial’. Jornal Vascular Brasileiro, vol. 18, 2019, p. e20180105. DOI.org (Crossref), https://doi.org/10.1590/1677-5449.180105.
  10. Sieblist, C., et al. ‘Ausgedehnte Lungenembolie bei Varikophlebitis’. Der Hautarzt, Vol. 61, No. 11, Nov. 2010, pp. 973–75. DOI.org (Crossref), https://doi.org/10.1007/s00105-010-1949-0.
  11. Cosmi, Benilde, et al. ‘Risk Factors for Recurrent Events in Subjects with Superficial Vein Thrombosis in the Randomized Clinical Trial SteFlux (Superficial Thromboembolism Fluxum)’. Thrombosis Research, vol. 133, no. 2, Feb. 2014, pp. 196–202. DOI.org (Crossref), https://doi.org/10.1016/j.thromres.2013.12.005.
  12. Mangiafico, Marco, and Luca Costanzo. ‘Superficial Venous Thrombosis: A Comprehensive Review’. Healthcare, vol. 12, no. 4, Feb. 2024, p. 500. DOI.org (Crossref), https://doi.org/10.3390/healthcare12040500.
  13. Key, Nigel S., et al. ‘Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update’. Journal of Clinical Oncology, vol. 38, no. 5, Feb. 2020, pp. 496–520. DOI.org (Crossref), https://doi.org/10.1200/JCO.19.01461.
  14. Schoot, Reineke A., et al. ‘Systemic Treatments for the Prevention of Venous Thrombo-Embolic Events in Paediatric Cancer Patients with Tunnelled Central Venous Catheters’. Cochrane Database of Systematic Reviews, edited by Cochrane Childhood Cancer Group, Sept. 2013. DOI.org (Crossref), https://doi.org/10.1002/14651858.CD009160.pub2.
  15. Iba, Toshiaki, et al. ‘Therapeutic Strategies in Patients with Coagulopathy and Disseminated Intravascular Coagulation: Awareness of the Phase-Dependent Characteristics’. Minerva Medica, vol. 112, no. 6, Feb. 2022. DOI.org (Crossref), https://doi.org/10.23736/S0026-4806.21.07469-3.
  16. Delluc, Aurélien, et al. ‘Outcome of Central Venous Catheter Associated Upper Extremity Deep Vein Thrombosis in Cancer Patients’. Thrombosis Research, vol. 135, no. 2, Feb. 2015, pp. 298–302. DOI.org (Crossref), https://doi.org/10.1016/j.thromres.2014.11.020.
  17. Leven, Cyril, et al. ‘Impact of Bariatric Surgery on Oral Anticoagulants Pharmacology, and Consequences for Clinical Practice: A Narrative Review’. Fundamental & Clinical Pharmacology, vol. 35, no. 1, Feb. 2021, pp. 53–61. DOI.org (Crossref), https://doi.org/10.1111/fcp.12587.
  18. Schmidt, Robert A., et al. ‘Patient Characteristics and Long–Term Outcomes beyond the First 6 Months after a Diagnosis of Cancer-Associated Venous Thromboembolism’. Thrombosis Research, vol. 188, Apr. 2020, pp. 106–14. DOI.org (Crossref), https://doi.org/10.1016/j.thromres.2020.02.005.
  19. Blokhin, Ilya O., and Steven R. Lentz. ‘Mechanisms of Thrombosis in Obesity’: Current Opinion in Hematology, vol. 20, no. 5, Sept. 2013, pp. 437–44. DOI.org (Crossref), https://doi.org/10.1097/MOH.0b013e3283634443.
  20. Hotoleanu, Cristina. ‘Association between Obesity and Venous Thromboembolism’. Medicine and Pharmacy Reports, Mar. 2020. DOI.org (Crossref), https://doi.org/10.15386/mpr-1372.
  21. Li R, Chen Z, Gui L, Wu Z, Miao Y, Gao Q, Diao Y, Li Y. Varicose Veins and Risk of Venous Thromboembolic Diseases: A Two-Sample-Based Mendelian Randomization Study. Front Cardiovasc Med. 2022 Apr 14;9:849027. doi: 10.3389/fcvm.2022.849027. PMID: 35498031; PMCID: PMC9047357.
  22. van Vlijmen EF, Wiewel-Verschueren S, Monster TB, Meijer K. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2016 Jul;14(7):1393-403. doi: 10.1111/jth.13349. Epub 2016 Jun 16. PMID: 27121914.
  23. Meaidi, Amani, et al. ‘Venous Thromboembolism with Use of Hormonal Contraception and Non-Steroidal Anti-Inflammatory Drugs: Nationwide Cohort Study’. BMJ, Sept. 2023, p. e074450. DOI.org (Crossref), https://doi.org/10.1136/bmj-2022-074450.
  24. Gronich, N., et al. ‘Higher Risk of Venous Thrombosis Associated with Drospirenone-Containing Oral Contraceptives: A Population-Based Cohort Study’. Canadian Medical Association Journal, vol. 183, no. 18, Dec. 2011, pp. E1319–25. DOI.org (Crossref), https://doi.org/10.1503/cmaj.110463.
  25. Varrias, Dimitrios, et al. ‘Venous Thromboembolism in Pregnancy: Challenges and Solutions’. Vascular Health and Risk Management, vol. 19, 2023, pp. 469–84. PubMed, https://doi.org/10.2147/VHRM.S404537.
  26. https://www.rcog.org.uk/media/wj2lpco5/gtg-37b-1.pdf
  27. Kelly, J., et al. ‘Dehydration and Venous Thromboembolism after Acute Stroke’. QJM: An International Journal of Medicine, vol. 97, no. 5, May 2004, pp. 293–96. DOI.org (Crossref), https://doi.org/10.1093/qjmed/hch050.
  28. Elias, Saad, et al. ‘Dehydration as a Possible Cause of Monthly Variation in the Incidence of Venous Thromboembolism’. Clinical and Applied Thrombosis/Hemostasis, vol. 22, no. 6, Sept. 2016, pp. 569–74. DOI.org (Crossref), https://doi.org/10.1177/1076029616649435.
  29. https://journals.sagepub.com/doi/pdf/10.1177/1076029612452781
  30. Manlhiot, Cedric, et al. ‘Risk, Clinical Features, and Outcomes of Thrombosis Associated With Pediatric Cardiac Surgery’. Circulation, vol. 124, no. 14, Oct. 2011, pp. 1511–19. DOI.org (Crossref), https://doi.org/10.1161/CIRCULATIONAHA.110.006304.
  31. Kang KW, Lee JY, Lee BH, Jeon MJ, Yu ES, Kim DS, Lee SR, Choi CW, Park Y, Sung HJ, Kim BS. Postoperative Thromboembolism According to the Type of Surgery: A Nationwide Study in the Republic of Korea. J Clin Med. 2022 Mar 8;11(6):1477. doi: 10.3390/jcm11061477. PMID: 35329803; PMCID: PMC8948856.
  32. Singh, Tino, et al. ‘Timing of Symptomatic Venous Thromboembolism after Surgery: Meta-Analysis’. British Journal of Surgery, vol. 110, no. 5, Apr. 2023, pp. 553–61. DOI.org (Crossref), https://doi.org/10.1093/bjs/znad035.
  33. Adnan, Ghufran, et al. ‘Coronary Artery Thrombus’. StatPearls, StatPearls Publishing, 2025. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK534808/.
  34. Zezos, Petros. ‘Inflammatory Bowel Disease and Thromboembolism’. World Journal of Gastroenterology, vol. 20, no. 38, 2014, p. 13863. DOI.org (Crossref), https://doi.org/10.3748/wjg.v20.i38.13863.
  35. Gala D, Newsome T, Roberson N, Lee SM, Thekkanal M, Shah M, Kumar V, Bandaru P, Gayam V. Thromboembolic Events in Patients with Inflammatory Bowel Disease: A Comprehensive Overview. Diseases. 2022 Sep 30;10(4):73. doi: 10.3390/diseases10040073. PMID: 36278572; PMCID: PMC9589934.
  36. Thrombosis and inflammatory bowel disease
    Violi, Francesco et al.
    The Lancet, Volume 404, Issue 10463, 1641
  37. Al-Azzawi, HasanF, et al. ‘Nephrotic Syndrome-Induced Thromboembolism in Adults’. International Journal of Critical Illness and Injury Science, vol. 6, no. 2, 2016, p. 85. DOI.org (Crossref), https://doi.org/10.4103/2229-5151.183019.
  38. Parker K, Ragy O, Hamilton P, Thachil J, Kanigicherla D. Thromboembolism in nephrotic syndrome: controversies and uncertainties. Res Pract Thromb Haemost. 2023 Aug 9;7(6):102162. doi: 10.1016/j.rpth.2023.102162. PMID: 37680313; PMCID: PMC10480654.
  39. Violi, F., et al. ‘Pneumonia, Thrombosis and Vascular Disease’. Journal of Thrombosis and Haemostasis, vol. 12, no. 9, Sept. 2014, pp. 1391–400. DOI.org (Crossref), https://doi.org/10.1111/jth.12646.
Share

Dr. Neha Mistry

Bachelor of Dental Surgery- B.D.S., Mumbai, India

Dr. Neha Mistry has been in private dental practice since 2005, delivering personalized, high quality oral healthcare with a focus on patient comfort and long term well being. She specializes in smile design and dental implants.

arrow-right